The lysosomal thiol proteinases all belong to the papain superfamily, and their activity in the body is controlled by several endogenous proteinase inhibitors. Recent studies have shown that abnormal activity of thiol proteinase is involved in several inflammatory diseases, suggesting an important role for thiol proteinase inhibitors in the pathophysiology of disease.
cally stable agonists or antagonists of natural peptides, or enzyme inhibitors. [9] [10] [11] [12] [13] [14] [15] We now report the synthesis of pseudo-peptide analogs of Suc-Ala-Val-Val-Ala-Ala-pNA, in which each of the peptide bonds was consecutively reduced, and describe the relationship between structure and effect on thiol proteinase (papain); in addition, we examined the enzymatic breakdown of the peptides by papain using HPLC.
Cleavage of peptide bonds by papain reduces the inhibitory activity of the peptide toward papain. The reduced peptides, however, resist enzymatic degradation.
The synthetic route to the pseudo-peptide analog is shown in Fig. 2 . The pentapeptide was prepared stepwise, starting from the C-terminal residue, by the N-hydroxysuccinimide active-ester method, except for the pseudo-peptide bond. Boc-Ala-OH and Boc-Val-OH were converted into the corresponding aldehyde, 16) which could be stored for 6 months in a refrigerator after purification. Then, the aldehyde was reacted with the HBr salt of H-Ala-pNA according to the procedure of Martinez et al. 9) with a minor modification to obtain the desired pseudo-peptide. Purification of the peptide by Sephadex LH-20 column chromatography was very efficient after each, stepwise, elongation procedure. All peptides obtained here were homogeneous upon silica gel thin-layer chromatography and reversed-phase HPLC. The result of the elemental analysis for intermediates and the result of TOF-MS for 4 kinds of desired peptides and one of the intermediates were in good agreement with theoretically expected values (Fig.1, Table1) . The inhibitory activity of these synthetic peptides against papain was determined with a synthetic substrate, Bz-Arg-b NA, using techniques previously described 17) and the results are summarized in Figs mM), Suc-Ala-Val-Val-Ala-Ala-pNA (as potent as the former)]. 7) In particular peptide 2 is about 10-fold as active as the parent peptide (IC 50 =8 mM). When the results were plotted according to the method of Lineweaver and Burk, peptide 1 and 2 inhibited papain non-competitively (Fig.5) , like SucGln-Val-Val-Ala-Ala-pNA reported previously.
7)
Thus, it is clear that substitution of the peptide bond is responsible for the strong activity which may result from increased flexibility of the structure or increased resistance to proteinase (papain). Therefore, the stability of the parent peptide (Suc-Ala-Val-Val-Ala-Ala-pNA) to papain was tested by measuring the degradation products by HPLC. The expected products by papain (H-Ala-pNA, H-Ala-Ala-pNA, H-Val-Ala-Ala-pNA and H-Val-Val-Ala-Ala-pNA) were prepared by deblocking the N a -protecting groups of the corresponding protected peptides in the usual manner. Incubation of Suc-Ala-Val-Val-Ala-Ala-pNA with papain in phosphate buffer at 37°C caused a rapid decline of the parent peptide peak. Moreover, the appearance of peaks for HAla-Ala-pNA and H-Ala-pNA appeared at the same time as the disappearance of the Suc-Ala-Val-Val-Ala-Ala-pNA peak, which strongly suggests enzymatic breakdown of the peptide inhibitor (Fig. 6 ). The strong inhibitory activity of peptide 1 and peptide 2, therefore, could be attributed to their resistance to enzymatic degradation by papain. The solubility of these 4 kinds of pseudo-peptides in water (over 1 mg/1 ml) as greater than for lead compounds such as SucAla-Val-Val-Ala-Ala-pNA. The HPLC characteristics of these peptides also indicated their hydrophilicity (Fig. 7) , which seems to favor solubility in buffer.
Experimental
The melting points are uncorrected. Optical rotations were measured with an automatic polarimeter, model DIP-360 (Japan Spectroscopic Co., Ltd.). Amino acid compositions of acid hydrolysates (6 N HCl, 110°C, 18 h; for peptides containing a Val-Val bond, 6 N HCl, 110°C, 72 h) were determined with an amino acid analyzer, K-101 AS (Kyowa Seimitsu Co., Ltd. Analytical reversed-phase HPLC was performed on a Waters M-600 model using a YMC-Pack Pro C 18 AS-303 (0.46ϫ25 cm) column and a linear gradient of water (A) and acetonitrile (B), both containing 0.05%TFA, at a flow rate of 1 ml/min. The following gradient systems were used: B: 15 to 50% (20 min). TOF-MS was conducted using a Kratos Kompact MALD/I 3 mass spectrometer. The samples were dissolved in MeOH and matrix was used. Papain was purchased from Nacalai Tesque (code 260-36, 17 U/mg protein)
N-Methoxy-N-methyl-a-(tert-butoxycarbonylamino)-carboxamides and a-(tert-butoxycarbonylamino)-aldehydes were prepared according to the procedure of Martinez et al. 9) and others. 16, 18, 19) (tert-Butoxycarbonyl)-L-valine N,O-Dimethylhydroxamate Boc-L-Val-OH (8.45 g, 38.9 mmol) was dissolved in DMF (50 ml) containing the hydrochloride salt of N,O-dimethylhydroxylamine (3.9 g, 40 mmol). Bopreagent (17.4 g, 38.9 mmol) was added, followed by Et 3 N (5.5 ml, 50 mmol). The reaction mixture was stirred at 4°C overnight. The solvent was removed in vacuo and the residue was dissolved in AcOEt (250 ml) and washed with a 5% citric acid solution (3ϫ50 ml), saline (3ϫ50 ml), saturated sodium bicarbonate solution (3ϫ50 ml) and saline (3ϫ50 ml). The organic layer was dried over MgSO 4 Lithium aluminum hydride (1.5 g,) was added to a stirred solution of (tert-butoxycarbonyl)-L-valine N,O-dimethylhydroxamate (10 g, 38.9 mmol) in dry ether (100 ml), at Ϫ20°C. Reduction was complete in 1 h. The mixture was hydrolyzed with a solution of 10% citric acid (ca. 50 ml) instead of potassium hydrogen sulfate. The aqueous phase was separated and extracted with ether (200 mlϫ3), which was then washed with 10% citric acid, saline, 5% sodium bicarbonate solution and saline. The organic layer was dried over sodium sulfate and concentrated in vacuo. The oily residue was left standing overnight in a refrigerator. The crystalline compound produced was triturated and filtered with hexane. 74 mmol) was treated with TFA (2 ml) for 1 h and the addition of ether (100 ml) yielded a white powder which was collected by filtration and dried in vacuo over KOH]. Sodium cyanoborohydride (207 mg, 3.3 mmol ) was added in small portions over 30 min. After 1 h, when no more TFA salt could be detected by TLC, the reaction mixture was cooled in an ice-water bath, and saturated sodium bicarbonate solution (30 ml) was added under stirring. AcOEt (100 ml) was added to the reaction mixture. The organic layer was collected, then washed with saturated sodium bicarbonate solution, saline, 5% citric acid solution and saline, and dried over MgSO 4 . The solution was concentrated in vacuo to yield an oil that was triturated with ether to give a white powder. Yield 620 mg (48.6%), mp 178-180°C. Physical constants and analytical data are shown in Table 1 .
Boc-Ala-Val-y y-(CH 2 -NH)-Val-Ala-Ala-pNA (One of the Typical Active Ester Condensation Procedures) Boc-Ala-ONSu (0.152 g, 0.531 mmol) and H-Val-y-(CH 2 -NH)-Val-Ala-Ala-pNA. TFA [prepared from 0.3 g (0.531 mmol) Boc-Val-y-(CH 2 -NH)-Val-Ala-Ala-pNA and 1 ml TFA] were dissolved in DMF (15 ml) containing Et 3 N (0.112 ml, 0.797 mmol). The reaction mixture was stirred at room temperature overnight. Boc-AlaONSu (50 mg, 0.175 mmol) was added to the reaction mixture which was stirred for several hours. After removal of the solvent, EtOH (2 ml) was added to the residue which was applied to a Sephadex LH-20 column (2.2ϫ125 cm), equilibrated and eluted with EtOH directly. Fractions (5 g each) were collected. After removal of the solvent of the appropriate eluent (fraction Nos. 26-30), ether was added to the residue to give an amorphous powder which included a small amount of impurity [Rf 1 0.24 (main spot), 0.27 (impurity)]. This powder was purified by silica gel column chromatography (2.7ϫ30 cm) using 3% MeOH in CHCl 3 as eluent. The pure fraction (Rf 1 0.24) was pooled and the solvent was removed in vacuo. The residue was crystallized spontaneously, and was triturated with hexane to yield crystalline compound. The crystalline compound was collected by filtration, rinsed with a small amount of ether, and dried in vacuo. Yield 245 mg (72.7%). Physical constants and analytical data are shown in Table 1 . Vol. 47, No. 3 Suc-Ala-Val-y y-(CH 2 -NH)-Val-Ala-Ala-pNA (General Procedure for the Preparation of Suc-Peptides) H-Ala-Val-y-(CH 2 -NH)-Val-Ala-AlapNA [prepared from 100 mg (0.157 mmol) Boc-Ala-Val-(CH 2 -NH)-ValAla-Ala-pNA and 1 ml TFA] was dissolved in pyridine (2 ml) and Et 3 N (22 ml, 0.157 mmol). Succinic anhydride (47.2 mg, 0.472 mmol) was added to the above solution at 0°C and the reaction mixture was stirred at room temperature overnight. After removal of solvent, EtOH was added to the residue which was then subjected to Sephadex LH-20 column (1.3ϫ135 cm) chromatography, using EtOH as an eluent. Fractions (6 g each) were collected. After removal of the solvent of the appropriate eluent (fraction Nos. [13] [14] , ether was added to the residue to afford crystals, which were collected by filtration and dried in vacuo. Yield 53.5 mg (52.5%), Rf 2 0.4. Physical constants and analytical data are shown in Table 1 .
HPLC Analyses of Suc-Ala-Val-Val-Ala-Ala-pNA Degradation by Papain Analytical reversed-phase HPLC was performed on a Waters M-600 model using a YMC-Pack Pro C 18 AS-303 (0.46ϫ25 cm) column and a linear gradient of water (A) and acetonitrile (B), both containing 0.05%TFA, at a flow rate of 1 ml/min. The following gradient system was used: B: 15 to 50% (20 min). Absorbance was monitored at 220 nm.
Preparation of the samples: Papain (0.3 mg) was dissolved in 500 ml 0.1 M phosphate buffer (pH 6.0). Peptide (1.3 mg) was dissolved in a mixture of phosphate buffer (100 ml) and DMSO (100 ml). Both solutions (50 ml each) were mixed, then incubated in a water-bath at 37°C.
After incubation of the combined samples of the parent peptide (Suc-AlaVal-Val-Ala-Ala-pNA) and papain, in 0.1 M phosphate buffer (pH 6.0) containing DMSO at 37°C for 3 min, over 90% of the parent peptide remained intact. After incubation for 20 min less than 5% of the parent peptide remained intact, with the formation of almost an equal amount of metabolite [retention time (RT) 12.3 min], H-Ala-pNA and metabolite (RT 17.2 min,HAla-Ala-pNA). When the incubation period was extended to 1 h, the HPLC profile was similar to that after a 20 min incubation. The appearance of the metabolites mirrored the disappearance of the parent peptide, which strongly suggested enzymatic breakdown of the synthetic inhibitors. N a a -Deprotection: Free peptide analogs were prepared by the following procedure. The N a -protecting group, Boc was cleaved by TFA (ca. 1 ml per 100 mg peptide) at ice-bath temperature for 60 min. After removal of the TFA in vacuo at 15-20°C, the residue was treated with dry ether. If a powder was obtained, it was collected by filtration, dried over KOH pellets in vacuo for 3 h and then used as the standard sample.
Z-Ala-pNA was treated with 25%HBr/AcOH as described in our previous report.
7)
The TFA salt of H-Ala-Ala-pNA (3 mg), H-Val-Ala-Ala-pNA (4 mg), HVal-Val-Ala-Ala-pNA (5 mg) and the HBr salt of H-Ala-pNA (2 mg) were dissolved in water or DMSO (0.5-1.0 ml) for injection.
